Information regarding the generic availability of Austedo is limited at this time. Austedo (deuterated deutetrabenazine) is an oral medication used to treat chorea associated with Huntington's disease and tardive dyskinesia [1].
When does Austedo's patent expire?
The exact patent expiration date for Austedo is not publicly available. Patent protection for medications can be complex, involving multiple patents covering different aspects of the drug, such as its composition, method of use, and manufacturing process. Companies that develop generic versions of a drug typically await the expiration of relevant patents to enter the market. Information on specific drug patents and their expiry can often be found through specialized databases [2].
What are the challenges to Austedo's market exclusivity?
Challenges to a drug's market exclusivity can arise from patent litigation, where generic manufacturers may challenge the validity or infringement of existing patents. Successful challenges can lead to earlier generic entry than originally anticipated. Additionally, regulatory pathways exist for generic drug approval, which can influence when a generic product becomes available.
How does Austedo work?
Austedo is a vesicular monoamine transporter 2 (VMAT2) inhibitor. It works by reducing the amount of certain chemicals, specifically dopamine, in the brain. This reduction helps to control involuntary movements associated with conditions like Huntington's disease and tardive dyskinesia [1].
What are the risks associated with Austedo?
Austedo carries a risk of serious side effects, including depression and suicidal thoughts or behavior, and neuroleptic malignant syndrome (NMS), a rare but potentially fatal condition. Other common side effects include somnolence, fatigue, insomnia, and parkinsonism [1].
Who manufactures Austedo?
Teva Pharmaceuticals manufactures Austedo [1].